Clinical trial
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected…
NCT00484341 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00484341 |
|---|---|
| Title | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. |
| Official title | NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS) |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Adult Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | low-dose NGR-hTNF, high-dose NGR-hTNF, Doxorubicin |
| Enrollment | 69 |
| Start date | Oct 1, 2010 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2016 |
| First posted | Jun 8, 2007 |
| Last update posted | Aug 29, 2018 |
| Countries | France, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: